Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

about

Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

Item

http://www.wikidata.org/entity/Q44679554

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

@en

Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

@nl

type

Item

label

Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

@en

Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

@nl

prefLabel

Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

@en

Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

@nl

P1476

Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.

@en

P2093

Peter Martin

http://www.w3.org/2001/XMLSchema#string

Tiffany Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

The phosphoinositide 3-kinase pathway

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

G1 phase progression: cycling on cue

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

P2888

s11899-014-0221-6

P304

254-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-014-0221-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25023397

http://www.w3.org/2001/XMLSchema#string